Jounce Therapeutics, Inc.
JNCE · NASDAQ
12/31/2022 | 9/30/2022 | 6/30/2022 | 3/31/2022 | |
|---|---|---|---|---|
| Revenue | $82 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $82 | $0 | $0 | $0 |
| % Margin | 100% | – | – | – |
| R&D Expenses | $23 | $24 | $26 | $30 |
| G&A Expenses | $8 | $8 | $8 | $7 |
| SG&A Expenses | $8 | $8 | $8 | $7 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $32 | $31 | $34 | $37 |
| Operating Income | $50 | -$31 | -$34 | -$37 |
| % Margin | 61.4% | – | – | – |
| Other Income/Exp. Net | -$52 | $0 | $0 | $0 |
| Pre-Tax Income | $51 | -$31 | -$34 | -$37 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | $51 | -$31 | -$34 | -$37 |
| % Margin | 62.1% | – | – | – |
| EPS | 0.99 | -0.6 | -0.65 | -0.72 |
| % Growth | 265% | 7.7% | 9.7% | – |
| EPS Diluted | 0.99 | -0.6 | -0.65 | -0.72 |
| Weighted Avg Shares Out | 52 | 52 | 52 | 52 |
| Weighted Avg Shares Out Dil | 52 | 52 | 52 | 52 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $1 | $1 |
| EBITDA | $51 | -$31 | -$33 | -$37 |
| % Margin | 61.9% | – | – | – |